News
FY2025 Appropriations
We are tracking the status of FY2025 appropriations, where things stand, and what it all means for bond lawyers.
Four Key Takeaways from The Workshop 2024
New leadership, new ideas, and the new Model Bond Opinion Report. Here’s a recap from this year’s conference and what you may have missed.
A Message from Outgoing NABL President, Carol McCoog
Recapping a few of the organization’s many successes throughout the past year.
2024 NABL Awards
Each year, we celebrate dedicated members and municipal market champions with a variety of awards to honor their contributions to our organization and industry.
2024 Presidential Election: Where They Stand on Munis
Neither candidate’s policy platform offers many details on municipal bonds, but we still have some ideas.
Agencies Release FDTA Proposed Joint Rule
While not final, the FDIC’s draft proposed rule offers insights into the work of covered agencies to implement the Financial Data Transparency Act (FDTA).
Unpacking the New Model Bond Opinion Report
After more than 20 years, we will release an updated version of our signature resource, the Model Bond Opinion Report, this September.
Five Must Read NABL Resources
Since 1979, the National Association of Bond Lawyers (NABL) has been providing public finance legal professionals with relevant resources to help advance our industry and promote the integrity of the…
Judicial Watch 2024: Admin Power and Establishment Clause Cases
A pair of recent SCOTUS rulings could reshape agency rulemaking and enforcement powers, and a case out of Oklahoma could be the next front in establishment clause questions.
Seven NABL Webinars You Need to Watch
These webinars are designed to fit into your busy schedule, allowing you to access a wealth of knowledge and expertise at your convenience.
1st Circuit Reverses District Court Opinion in PREPA Revenue Bond Case
Long-awaited opinion in Puerto Rico bankruptcy case may help settle uncertainties in the municipal market.
DEA Rescheduling of Marijuana
Regulators have proposed moving marijuana from a Schedule I to Schedule III drug. What do we know and what do we not know?